XTX Topco Ltd Takes $112,000 Position in TScan Therapeutics, Inc. (NASDAQ:TCRX)

XTX Topco Ltd acquired a new stake in TScan Therapeutics, Inc. (NASDAQ:TCRX) during the third quarter, Holdings Channel.com reports. The firm acquired 22,438 shares of the company’s stock, valued at approximately $112,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp bought a new position in shares of TScan Therapeutics in the second quarter valued at approximately $682,000. Rhumbline Advisers bought a new position in TScan Therapeutics in the 2nd quarter worth $274,000. American Century Companies Inc. lifted its position in TScan Therapeutics by 48.9% during the 2nd quarter. American Century Companies Inc. now owns 47,481 shares of the company’s stock worth $278,000 after acquiring an additional 15,596 shares during the last quarter. Cornercap Investment Counsel Inc. bought a new stake in TScan Therapeutics during the second quarter valued at about $134,000. Finally, Brown Brothers Harriman & Co. acquired a new stake in shares of TScan Therapeutics in the second quarter valued at about $445,000. 82.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction dated Monday, September 23rd. The shares were bought at an average cost of $5.29 per share, for a total transaction of $26,450.00. Following the purchase, the director now owns 45,000 shares in the company, valued at approximately $238,050. This trade represents a 12.50 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.76% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on TCRX shares. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research note on Wednesday, December 11th. Wedbush reissued an “outperform” rating and issued a $7.00 price objective (down from $10.00) on shares of TScan Therapeutics in a research report on Tuesday, December 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Wednesday, December 11th.

TScan Therapeutics Trading Up 1.4 %

TScan Therapeutics stock opened at $2.97 on Friday. The business has a 50 day moving average price of $4.57 and a two-hundred day moving average price of $5.68. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.13. TScan Therapeutics, Inc. has a 12 month low of $2.60 and a 12 month high of $9.69. The stock has a market cap of $158.51 million, a price-to-earnings ratio of -2.80 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.03. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The business had revenue of $1.05 million during the quarter, compared to analyst estimates of $2.86 million. As a group, equities analysts forecast that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

TScan Therapeutics Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.